Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · April 16, 2015

Maintenance Treatment With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer

The Lancet

 

Additional Info

The Lancet
Maintenance Treatment With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer (CAIRO3): A Phase 3 Randomised Controlled Trial of the Dutch Colorectal Cancer Group
Lancet 2015 Apr 07;[EPub Ahead of Print], LH Simkens, H van Tinteren, A May, AJ Ten Tije, GJ Creemers, OJ Loosveld, FE de Jongh, FL Erdkamp, Z Erjavec, AM van der Torren, J Tol, HJ Braun, P Nieboer, JJ van der Hoeven, JG Haasjes, RL Jansen, J Wals, A Cats, VA Derleyn, AH Honkoop, L Mol, CJ Punt, M Koopman

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading